United Health (UNH.US) results beat analysts' expectations
United Health (UNH.US), the leading U.S. healthcare and insurance company, reported results that significantly beat analysts' expectations. Treatment costs were lower than expected, easing concerns about the high cost of Medicare Advantage in June due to an increase in planned outpatient surgeries. Results:
Start investing today or test a free demo
Create account Try a demo Download mobile app Download mobile app- Revenue: $92.36 billion vs. $91.4 billion expected (14.2% year-over-year growth)
- Earnings per share (EPS): $6.56 vs. $6.33 expected (13.3% year-over-year growth, breaking a three-quarter streak of declining net income)
The company added 55,000 new members to its Medicare Advantage program, while the number of people served under Medicaid fell by 290,000. The number of customers in the U.S. domestic market increased by 75,000. Revenues for the Optum Health division increased 22% to $56.7 billion, driven by the acquisition of Change Healthcare. Revenue per patient served at Optum increased 27% in the third quarter. The company raised its earnings per share guidance for the full year 2023 to a range of $24.85-$25 from $24.70-$25 previously (according to FactSet data, the EPS consensus was $24.83). Jefferies analysts said that the decline in costs should further limit market concerns in the current quarter. The company reported higher customer numbers and expanded its service offerings:
Source: xStation5
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
